Covered recipient · General Payments record
RAFIK ABADIER
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$3,321.33
24 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $2,387.67 | 8 |
| Food and Beverage | $933.66 | 16 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ModernaTX, Inc. | $1,817.81 | 5 |
| Bayer Healthcare Pharmaceuticals Inc. | $1,277.44 | 9 |
| Lexicon Pharmaceuticals, Inc. | $65.97 | 3 |
| Boston Scientific Corporation | $63.90 | 1 |
| Novartis Pharmaceuticals Corporation | $36.40 | 2 |
| AstraZeneca Pharmaceuticals LP | $31.17 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.57 | 1 |
| E.R. Squibb & Sons, L.L.C. | $14.07 | 1 |
Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RAFIK ABADIER
NPI 1649253147 · CMS profile ID 256213
Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
INVERNESS, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1649253147?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649253147?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649253147?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1649253147?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
24 matching records · $3,321.33 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–24 of 24.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. | $21.05 | 12/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1080523315 | CMS |
| Novartis Pharmaceuticals Corporation | $17.46 | 10/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991439153 | CMS |
| Lexicon Pharmaceuticals, Inc. | $23.35 | 09/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040749333 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.99 | 08/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011660889 | CMS |
| Lexicon Pharmaceuticals, Inc. | $21.57 | 07/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040749327 | CMS |
| ModernaTX, Inc. | $889.15 | 07/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056981581 | CMS |
| ModernaTX, Inc. | $150.00 | 07/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056981589 | CMS |
| ModernaTX, Inc. | $297.72 | 07/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056981701 | CMS |
| ModernaTX, Inc. | $325.00 | 07/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056981705 | CMS |
| ModernaTX, Inc. | $155.94 | 07/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056981709 | CMS |
| Novartis Pharmaceuticals Corporation | $18.94 | 06/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991439133 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.18 | 05/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015828103 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.57 | 05/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996471561 | CMS |
| Boston Scientific Corporation | $63.90 | 05/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021885189 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $34.28 | 04/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000421563 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $34.28 | 04/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000421571 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $75.42 | 04/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000422795 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $78.67 | 04/22/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000422995 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $89.13 | 04/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000423353 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $141.49 | 04/22/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000425341 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $463.80 | 04/22/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000426529 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $149.47 | 04/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000425485 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $210.90 | 04/21/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000426009 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.07 | 02/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016044363 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $731.79 | 4 |
| PY2025 | Principal investigator | $554,369.24 | 96 |
| PY2024 | Principal investigator | $1,358,878.08 | 258 |
| PY2023 | Principal investigator | $1,095,651.17 | 1,020 |
| PY2022 | Principal investigator | $767,493.58 | 1,505 |
| PY2021 | Principal investigator | $331,251.89 | 220 |
| PY2020 | Principal investigator | $152,753.28 | 147 |
| PY2019 | Principal investigator | $85,046.12 | 52 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
258 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170813 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170817 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170819 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170821 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170823 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170825 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170827 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170829 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170831 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 12/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170833 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,919.73 | 12/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Noninterventional Study to Evaluate Inflammatory Biomarkers in Different Patient Populations Compared to Healthy Participants. | No dispute reported | 06/30/2026 | 1136398516 |
| Principal investigator 1 | ModernaTX, Inc. | $13,998.13 | 12/23/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147192362 |
| Principal investigator 1 | ModernaTX, Inc. | $34,902.97 | 12/19/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147192358 |
| Principal investigator 1 | ModernaTX, Inc. | $33,221.52 | 12/06/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192270 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 12/06/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192272 |
| Principal investigator 1 | ModernaTX, Inc. | $16,128.17 | 12/06/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192274 |
| Principal investigator 1 | ModernaTX, Inc. | $2,600.00 | 12/02/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192276 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170811 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170835 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170837 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171007 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171009 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171011 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171013 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171015 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171017 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 11/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171019 |
| Principal investigator 1 | ModernaTX, Inc. | $183,061.63 | 11/27/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147192352 |
| Principal investigator 1 | ModernaTX, Inc. | $10,000.00 | 11/11/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147192356 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $15,000.00 | 11/05/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Noninterventional Study to Evaluate Inflammatory Biomarkers in Different Patient Populations Compared to Healthy Participants. | No dispute reported | 06/30/2026 | 1136398512 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $210.00 | 11/01/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121155830 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $243.00 | 11/01/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121155832 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170815 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171021 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171023 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171025 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171027 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171029 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171031 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171033 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171035 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 10/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121171037 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,381.00 | 10/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121155822 |
| Principal investigator 1 | ModernaTX, Inc. | $7,250.00 | 10/21/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147192340 |
| Principal investigator 1 | ModernaTX, Inc. | $1,800.00 | 10/21/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147192342 |
| Principal investigator 1 | ModernaTX, Inc. | $102.45 | 10/15/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147192350 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $81.00 | 10/14/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121155826 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $405.00 | 10/14/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121155828 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 10/14/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147192348 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $81.00 | 10/09/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121155824 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,381.00 | 10/02/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121155820 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170737 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170739 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170741 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170743 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170745 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170747 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170749 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170751 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170753 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 09/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170755 |
| Principal investigator 1 | ModernaTX, Inc. | $9,000.00 | 09/12/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147192328 |
| Principal investigator 1 | ModernaTX, Inc. | $399.12 | 09/12/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1147192338 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,586.00 | 09/04/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121155546 |
| Principal investigator 1 | ModernaTX, Inc. | $2,719.49 | 09/04/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1147192268 |
| Principal investigator 1 | ModernaTX, Inc. | $12,529.35 | 09/02/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147192334 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170757 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170759 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170761 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170763 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170765 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170785 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170787 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170789 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170791 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 08/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170793 |
| Principal investigator 1 | ModernaTX, Inc. | $11,365.00 | 08/23/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192252 |
| Principal investigator 1 | ModernaTX, Inc. | $1,575.00 | 08/23/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192254 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 08/23/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192256 |
| Principal investigator 1 | ModernaTX, Inc. | $1,659.00 | 08/23/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192258 |
| Principal investigator 1 | ModernaTX, Inc. | $600.00 | 08/23/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192260 |
| Principal investigator 1 | ModernaTX, Inc. | $2,250.00 | 08/23/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192262 |
| Principal investigator 1 | ModernaTX, Inc. | $4,379.00 | 08/23/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192264 |
| Principal investigator 1 | ModernaTX, Inc. | $650.00 | 08/23/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192266 |
| Principal investigator 1 | ModernaTX, Inc. | $598.68 | 08/21/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147192326 |
| Principal investigator 1 | ModernaTX, Inc. | $7,517.61 | 08/01/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147192322 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170735 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170767 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170769 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170771 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170773 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170775 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170777 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170779 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170781 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170783 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 07/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170795 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170797 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 07/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170799 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6.00 | 07/18/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170801 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6.00 | 07/18/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170803 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6.00 | 07/18/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170805 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6.00 | 07/18/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170807 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6.00 | 07/18/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170809 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 07/17/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192246 |
| Principal investigator 1 | ModernaTX, Inc. | $4,384.23 | 07/17/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192248 |
| Principal investigator 1 | ModernaTX, Inc. | $10,000.00 | 07/17/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192250 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170697 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170699 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170701 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170703 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170705 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170707 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170709 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170711 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170713 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170715 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170717 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170719 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170721 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170723 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170725 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170727 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170729 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170731 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 06/28/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170733 |
| Principal investigator 1 | ModernaTX, Inc. | $25,058.70 | 06/28/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147192318 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $31.90 | 06/03/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121155494 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,814.00 | 06/03/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121155496 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,102.00 | 06/03/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121155502 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,814.00 | 06/03/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121155540 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,102.00 | 06/03/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121155542 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170581 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170583 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170645 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170647 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170649 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170651 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170653 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170655 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170657 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170677 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170679 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170681 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170683 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170685 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170687 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170689 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170691 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170693 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 05/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170695 |
| Principal investigator 1 | ModernaTX, Inc. | $100.50 | 05/31/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147192314 |
| Principal investigator 1 | ModernaTX, Inc. | $1,766.61 | 05/29/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147192312 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,381.00 | 05/01/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121155500 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170577 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170579 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170585 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170587 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170589 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170591 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170593 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170639 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170641 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170643 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170659 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170661 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170663 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170665 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170667 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170669 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170671 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170673 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 04/30/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170675 |
| Principal investigator 1 | ModernaTX, Inc. | $5,550.00 | 04/19/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147192308 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 04/17/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147192306 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,381.00 | 04/01/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121155498 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170455 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170457 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170459 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170461 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170463 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170465 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170467 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170469 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170509 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170511 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170513 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170515 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170517 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170519 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170521 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170523 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170525 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170527 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170529 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170531 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 03/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170533 |
| Principal investigator 1 | ModernaTX, Inc. | $7,605.90 | 03/28/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147192302 |
| Principal investigator 1 | ModernaTX, Inc. | $105,212.41 | 03/21/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147192290 |
| Principal investigator 1 | ModernaTX, Inc. | $15,211.80 | 03/21/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147192298 |
| Principal investigator 1 | ModernaTX, Inc. | $6,695.00 | 03/20/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH, LLC - INVERNESS | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147181313 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $514.40 | 03/04/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121155488 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,872.00 | 03/04/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121155490 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $397.10 | 03/04/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121155492 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170535 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170537 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170539 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170541 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170543 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170545 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170547 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170549 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170551 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170553 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170555 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170557 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170559 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170561 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170563 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170565 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170567 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170569 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170571 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170573 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 02/29/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170575 |
| Principal investigator 1 | ModernaTX, Inc. | $5,299.83 | 02/26/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147192288 |
| Principal investigator 1 | ModernaTX, Inc. | $88,151.74 | 02/23/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192238 |
| Principal investigator 1 | ModernaTX, Inc. | $87,493.26 | 02/23/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147192240 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $198,752.00 | 02/13/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH LLC | A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure | No dispute reported | 06/30/2026 | 1089695431 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $96,140.02 | 02/01/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | DDI Study CYP3A4/p-gp (perp) Inducer [patient study] - An Open-label, Single-sequence Study to Evaluate the Effect of Coadministration of Danicamtiv on the Pharmacokinetics of Midazolam in Patients With Stable Heart Failure With Reduced Ejection Fraction | No dispute reported | 06/30/2026 | 1123478603 |
| Principal investigator 1 | ModernaTX, Inc. | $5,771.25 | 02/01/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1147192242 |
| Principal investigator 1 | ModernaTX, Inc. | $43,190.75 | 02/01/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1147192244 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170451 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170453 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170471 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170473 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170475 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170477 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170479 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170481 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170483 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170485 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170487 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170489 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170491 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170493 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170495 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170497 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170499 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170501 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1121170503 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170505 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 01/31/2024 | Non-covered Recipient Entity Nature Coast Clinical Research | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | No dispute reported | 06/30/2026 | 1121170507 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,839.50 | 01/30/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure | No dispute reported | 06/30/2026 | 1089691845 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $15,447.70 | 01/30/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH LLC | A Randomized, Participant and Investigator Blinded, Sponsor Open-label, Placebo-controlled, Single Dose Study to Investigate the Safety and Tolerability of XXB750 in Heart Failure Participants With Reduced Ejection Fraction (HFrEF) | No dispute reported | 06/30/2026 | 1089695539 |
| Principal investigator 1 | ModernaTX, Inc. | $5,394.64 | 01/29/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 1147192278 |
| Principal investigator 1 | ModernaTX, Inc. | $33,948.18 | 01/16/2024 | Non-covered Recipient Entity NATURE COAST CLINICAL RESEARCH | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1147192282 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $175,714.81 | 01/10/2024 | Non-covered Recipient Entity NATURE COAST CLINIC RESEARCH | A Phase 2 Randomized Doubleblind Placebo-controlled Doseranging Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of AZD0780 in Participants with Dyslipidemi | No dispute reported | 06/30/2026 | 1110846995 |